Skip to main content

Indivi joins forces with Biogen

| News

Indivi joins forces with Biogen


Indivi and Biogen are cooperating on the development of digital biomarkers for Parkinson’s disease. To this end, the US biotech group is licensing its biomarker platform to Indivi. For its part, the Basel-based medtech company intends to merge Konectom with its dreaMS platform.

Indivi has entered into a partnership with Biogen. Through this collaboration with the US biotechnology group, Indivi plans to develop digital biomarkers for Parkinson’s disease, as the Basel-based medtech firm writes in a press release. To this end, Indivi intends to merge Biogen’s Konectom biomarker platform with its own digital biomarker platform for multiple sclerosis known as dreaMS.

“Through this multi-year strategic collaboration with Biogen, we aim to expand the reach of our unique technology to a new critical disease area where innovation is crucially needed and that may cross-fertilize with the progress of our scientific efforts in multiple sclerosis”, comments Guilhem Dupont, CEO of Indivi, before adding: “This collaboration is a testament to the hard work and dedication of our entire team over the past five years in developing transformative digital measurements to support research in neuroscience”.

Developments in other areas planned

The first step will involve Konectom being used in the Phase 2b LUMA study focused on an active ingredient for the treatment of early-stage Parkinson’s disease developed in conjunction with Denali Therapeutics. In addition, Biogen and Indivi are interested in jointly developing new digital endpoints for Parkinson’s. It is hoped that the merger of Konectom and dreaMS will lead to the development of digital measurement technology covering all key areas of neurology.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.